Di-n-propylessigsaure en es it fr

Di-n-propylessigsaure Brand names, Di-n-propylessigsaure Analogs

Di-n-propylessigsaure Brand Names Mixture

  • No information avaliable

Di-n-propylessigsaure Chemical_Formula


Di-n-propylessigsaure RX_link


Di-n-propylessigsaure fda sheet

Di-n-propylessigsaure msds (material safety sheet)

Di-n-propylessigsaure MSDS

Di-n-propylessigsaure Synthesis Reference

Oberreit, Ber.29, 1998 (1896)

Di-n-propylessigsaure Molecular Weight

144.211 g/mol

Di-n-propylessigsaure Melting Point

120 - 130 oC

Di-n-propylessigsaure H2O Solubility

Slightly soluble (1.3 mg/mL)

Di-n-propylessigsaure State


Di-n-propylessigsaure LogP


Di-n-propylessigsaure Dosage Forms

Capsule (250 mg); Syrup (250 mg drug/5mL syrup)

Di-n-propylessigsaure Indication

For use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.

Di-n-propylessigsaure Pharmacology

Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.

Di-n-propylessigsaure Absorption

Rapid absorption from gastrointestinal tract.

Di-n-propylessigsaure side effects and Toxicity

Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.

Di-n-propylessigsaure Patient Information

Since valproate products may produce CNS depression, especially when combined with another CNS depressant (eg, alcohol), patients should be advised not to engage in hazardous activities, such as driving an automobile or operating dangerous machinery, until it is known that they do not become drowsy from the drug.

Di-n-propylessigsaure Organisms Affected

Humans and other mammals